Tamarack Advisers’s Ascendis Pharma A/S ASND Stock Holding History

Tamarack Advisers’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,000	Closed	-$2.14M	–	36
2023 Q1	$2.14M	Sell	20,000 -25,000	-56%	-$2.86M	0.78%	23
2022 Q4	$5.5M	Buy	45,000 +30,000	+200%	+$3.48M	2.83%	13
2022 Q3	$1.55M	Hold	15,000	–	–	0.91%	30
2022 Q2	$1.39M	Buy	+15,000	New	+$1.41M	0.81%	27

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tamarack Advisers's ASND Position: Q2 2023 in Review

Tamarack Advisers sold out of Ascendis Pharma A/S (ASND) in Q2 2023, closing a stake of 20,000 shares — an estimated $2.14M sold.

Tamarack Advisers first reported a position in ASND in Q2 2022 and held it in 4 quarters. The position peaked at $5.5M in Q4 2022. 158 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

Tamarack Advisers reported no remaining Ascendis Pharma A/S position as of Q2 2023 after selling out during the quarter.
Tamarack Advisers sold 20,000 Ascendis Pharma A/S shares in Q2 2023, an estimated $2.14M.
Tamarack Advisers first reported a position in Ascendis Pharma A/S in Q2 2022 and held it in 4 quarters.
Tamarack Advisers's Ascendis Pharma A/S position peaked at $5.5M in Q4 2022.
158 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.